GE Medical Systems' bid for globalultrasound domination took a step forward last month when theFood and Drug Administration issued 510(k) marketing clearancefor its mid-range Logiq 500 scanner. GE now has the regulatorygo-ahead to sell both of the
GE Medical Systems' bid for globalultrasound domination took a step forward last month when theFood and Drug Administration issued 510(k) marketing clearancefor its mid-range Logiq 500 scanner. GE now has the regulatorygo-ahead to sell both of the scanners in the Logiq series.
Milwaukee-based GE lifted the wraps on Logiq 500 at the InternationalCongress of Radiology meeting in Singapore in January, two monthsafter Logiq 700 debuted at last year's Radiological Society ofNorth America conference (SCAN 4/6/94 and 12/15/93).
Logiq 500 is designed to be a more portable, economical versionof the premium Logiq 700. Logiq 500 features 64-channel all-digitalarchitecture and is half the size and weight of Logiq 700.
GE began marketing Logiq 500 in Asia late last year and inEurope earlier this year. GE will begin shipping the scanner inthe U.S. in August, according to the company. Shipments of Logiq700 will begin in October, after the company finishes rampingup its manufacturing operations and putting the final toucheson the system's software.
GE's ultrasound business also received ISO 9000 certificationin June, according to the company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.